Document Detail

Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension.
MedLine Citation:
PMID:  21139674     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Glaucoma is a collection of diseases characterized by multifactorial progressive changes leading to visual field loss and optic neuropathy most frequently due to elevated intraocular pressure (IOP). The goal of treatment is the lowering of the IOP to prevent additional optic nerve damage. Treatment usually begins with topical pharmacological agents as monotherapy, progresses to combination therapy with agents from up to 4 different classes of IOP-lowering medications, and then proceeds to laser or incisional surgical modalities for refractory cases. The fixed combination therapy with the carbonic anhydrase inhibitor dorzolamide hydrochloride 2% and the beta blocker timolol maleate 0.5% is now available in a generic formulation for the treatment of patients who have not responded sufficiently to monotherapy with beta adrenergic blockers. In pre- and postmarketing clinical studies, the fixed combination dorzolamide-timolol has been shown to be safe and efficacious, and well tolerated by patients. The fixed combination dorzolamide-timolol is convenient for patients, reduces their dosing regimen with the goal of increasing their compliance, reduces the effects of "washout" when instilling multiple drops, and reduces the preservative burden by reducing the number of drops administered per day.
Nicholas P Bell; José L Ramos; Robert M Feldman
Related Documents :
22939214 - Subfoveal choroidal thickness change following segmental scleral buckling for rhegmatog...
24304974 - Biting patterns and seasonality of anopheles gambiae sensu lato and anopheles funestus ...
9143424 - Evolution of the vertical reduction mammaplasty: the s approach.
20517084 - The combination of fibrin glue and quilting reduces drainage in the extended latissimus...
8416244 - The effect of embolization with n-butyl cyanoacrylate prior to surgical resection of ce...
24192904 - The use of an amino acid as a precursor of a bioactive metabolite in combatting an infe...
Publication Detail:
Type:  Journal Article     Date:  2010-11-22
Journal Detail:
Title:  Clinical ophthalmology (Auckland, N.Z.)     Volume:  4     ISSN:  1177-5483     ISO Abbreviation:  Clin Ophthalmol     Publication Date:  2010  
Date Detail:
Created Date:  2010-12-08     Completed Date:  2011-07-06     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  101321512     Medline TA:  Clin Ophthalmol     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  1331-46     Citation Subset:  -    
Robert Cizik Eye Clinic, Department of Ophthalmology and Visual Science, The University of Texas Medical School at Houston, Houston, Texas 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antiadenoviral effects of N-chlorotaurine in vitro confirmed by quantitative polymerase chain reacti...
Next Document:  Sympathetic ophthalmia after 23-gauge transconjunctival sutureless vitrectomy.